{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:03:41Z","timestamp":1784106221663,"version":"3.55.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Yokohama Foundation for the Advancement of Medical Science"},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Kidney Association-Nippon Boehringer Ingelheim Joint Research Program"},{"DOI":"10.13039\/501100004017","name":"Japanese Association of Dialysis Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009666","name":"Salt Science Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009666","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Strategic Research Project of Yokohama City University"},{"name":"Moriya Scholarship Foundation"},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayer Scholarship for Cardiovascular Research"},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJPF2303"],"award-info":[{"award-number":["JPMJPF2303"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017104","name":"Yokohama City University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autosomal-dominant polycystic kidney disease (ADPKD) is a genetic disorder frequently associated with non-dipper hypertension, with tolvaptan being the only currently approved treatment. However, the effects of tolvaptan on blood pressure (BP) in patients with ADPKD and hypertension remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study examined the effect of tolvaptan on 24-h ambulatory BP monitoring parameters. Changes in ambulatory BP-related parameters, including annual rate of change in total kidney volume (TKV), were assessed in 23 patients with ADPKD and hypertension before and after initiating tolvaptan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After initiation of tolvaptan, nocturnal systolic and diastolic BP dipping rates increased significantly, with systolic dipping rising from 9.61% to 14.0% (\u0394 \u2009+\u20094.39%; P\u2009=\u2009.014) and diastolic dipping from 10.48% to 14.66% (\u0394 \u2009+\u20094.18%; P\u2009=\u2009.023). The prevalence of a non-dipper BP profile decreased from 57% at baseline to 29% after treatment (P\u2009=\u2009.0339). In addition, the annual growth rate of TKV decreased from 13.6% to 1.61% (P\u2009&amp;lt;\u2009.0001), and the eGFR slope improved from \u22124.46 to \u22122.26 mL\/min\/1.73 m2\/year (P\u2009=\u2009.0431).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tolvaptan treatment was associated with improvements in nocturnal BP decline and diurnal BP patterns in patients with hypertension and ADPKD. In addition, a reduced rate of TKV growth and a slower decline in eGFR were observed. These findings provide further insight into the potential hemodynamic and renal effects of tolvaptan in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpag035","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:30:43Z","timestamp":1776771043000},"page":"1021-1029","source":"Crossref","is-referenced-by-count":0,"title":["Tolvaptan improves the diurnal blood pressure profile in patients with hypertension and autosomal-dominant polycystic kidney disease"],"prefix":"10.1093","volume":"39","author":[{"given":"Masaaki","family":"Hanaoka","sequence":"first","affiliation":[{"name":"Kohsaikai Kamioooka Jinsei Clinic , Yokohama,","place":["Japan"]},{"name":"Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine , Yokohama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9748-5811","authenticated-orcid":false,"given":"Hiromichi","family":"Wakui","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine , Yokohama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kanai","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine , Yokohama,","place":["Japan"]},{"name":"Department of Nephrology and Hypertension, Yokohama Minami Kyosai Hospital, Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Kinguchi","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine , Yokohama,","place":["Japan"]},{"name":"Department of Nephrology and Hypertension, Yokohama City University Medical Center, Yokohama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Azushima","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine , Yokohama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Kohsaikai Kamioooka Jinsei Clinic , Yokohama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-5372","authenticated-orcid":false,"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine , Yokohama,","place":["Japan"]},{"name":"Department of Nephrology and Hypertension, Yokohama City University Medical Center, Yokohama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"2026071504090410700_hpag035-B1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12882-015-0114-5","article-title":"A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease","volume":"16","author":"Woon","year":"2015","journal-title":"BMC Nephrol"},{"key":"2026071504090410700_hpag035-B2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2215\/CJN.02410508","article-title":"Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis","volume":"4","author":"Rizk","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026071504090410700_hpag035-B3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11906-023-01273-1","article-title":"Non-Dipping blood pressure or nocturnal hypertension: does one matter more?","volume":"26","author":"Tang","year":"2024","journal-title":"Curr Hypertens Rep"},{"key":"2026071504090410700_hpag035-B4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/j.ajkd.2004.04.026","article-title":"Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: a prehypertensive state","volume":"44","author":"Martinez-Vea","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2026071504090410700_hpag035-B5","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1007\/s00380-019-01411-3","article-title":"Clinical safety and efficacy of tolvaptan for acute phase therapy in patients with low-flow and normal-flow severe aortic stenosis","volume":"34","author":"Mitsui","year":"2019","journal-title":"Heart Vessels"},{"key":"2026071504090410700_hpag035-B6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000506118","article-title":"Long-term effects of high-dose tolvaptan for autosomal dominant polycystic kidney disease patients","volume":"10","author":"Nakatani","year":"2020","journal-title":"Case Rep Nephrol Dial"},{"key":"2026071504090410700_hpag035-B7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40265-019-1056-1","article-title":"Tolvaptan: a review in autosomal dominant polycystic kidney disease","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"2026071504090410700_hpag035-B8","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1161\/01.CIR.103.21.2579","article-title":"Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension","volume":"103","author":"Verdecchia","year":"2001","journal-title":"Circulation"},{"key":"2026071504090410700_hpag035-B9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/12.10.2075","article-title":"Ambulatory blood pressure in hypertensive patients with autosomal dominant polycystic kidney disease","volume":"12","author":"Li Kam Wa","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"2026071504090410700_hpag035-B10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1681\/ASN.V1051020","article-title":"Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease","volume":"10","author":"Valero","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2026071504090410700_hpag035-B11","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"2026071504090410700_hpag035-B12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40885-024-00265-w","article-title":"When and how to use ambulatory blood pressure monitoring and home blood pressure monitoring for managing hypertension","volume":"30","author":"Lee","year":"2024","journal-title":"Clin Hypertens"},{"key":"2026071504090410700_hpag035-B13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10157-009-0224-0","article-title":"Utility of the Japanese GFR estimation equation for evaluating potential donor kidney function","volume":"14","author":"Kakuta","year":"2010","journal-title":"Clin Exp Nephrol"},{"key":"2026071504090410700_hpag035-B14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000381476","article-title":"Kidney volume estimations with ellipsoid equations by magnetic resonance imaging in autosomal dominant polycystic kidney disease","volume":"129","author":"Higashihara","year":"2015","journal-title":"Nephron"},{"key":"2026071504090410700_hpag035-B15","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/HJH.0b013e328363e964","article-title":"European society of hypertension position paper on ambulatory blood pressure monitoring","volume":"31","author":"O\u2019Brien","year":"2013","journal-title":"J Hypertens"},{"key":"2026071504090410700_hpag035-B16","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(07)61538-4","article-title":"Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study","volume":"370","author":"Boggia","year":"2007","journal-title":"Lancet"},{"key":"2026071504090410700_hpag035-B17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/HYPERTENSIONAHA.108.115154","article-title":"Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease","volume":"53","author":"Pogue","year":"2009","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"2026071504090410700_hpag035-B18","first-page":"465","article-title":"[Perfect 24-hr blood pressure control using self-measured blood pressure and ambulatory blood pressure monitoring in chronic kidney disease]","volume":"51","author":"Kario","year":"2009","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"2026071504090410700_hpag035-B19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026071504090410700_hpag035-B20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000097366","article-title":"Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease","volume":"26","author":"Agarwal","year":"2006","journal-title":"Am J Nephrol"},{"key":"2026071504090410700_hpag035-B21","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archinternmed.2011.230","article-title":"Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease","volume":"171","author":"Minutolo","year":"2011","journal-title":"Arch Intern Med"},{"key":"2026071504090410700_hpag035-B22","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2020030236","article-title":"Prognostic significance of ambulatory BP monitoring in CKD: a report from the chronic renal insufficiency cohort (CRIC) study","volume":"31","author":"Rahman","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026071504090410700_hpag035-B23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/HYPERTENSIONAHA.115.06981","article-title":"Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the ambulatory blood pressure collaboration in patients with hypertension (ABC-H) meta-analysis","volume":"67","author":"Salles","year":"2016","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"2026071504090410700_hpag035-B24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41440-023-01368-x","article-title":"Nocturnal systolic blood pressure dipping and progression of chronic kidney disease","volume":"47","author":"Park","year":"2024","journal-title":"Hypertens Res"},{"key":"2026071504090410700_hpag035-B25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000368456","article-title":"Evening\u2014versus morning\u2014dosing drug therapy for chronic kidney disease patients with hypertension: a systematic review","volume":"39","author":"Liu","year":"2014","journal-title":"Kidney Blood Press Res"},{"key":"2026071504090410700_hpag035-B26","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1681\/ASN.2016111186","article-title":"Sleep-Time ambulatory BP is an independent prognostic marker of CKD","volume":"28","author":"Hermida","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026071504090410700_hpag035-B27","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1681\/ASN.2020101512","article-title":"The effect of tolvaptan on BP in polycystic kidney disease: a post hoc analysis of the TEMPO 3:4 trial","volume":"32","author":"Heida","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026071504090410700_hpag035-B28","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2026071504090410700_hpag035-B29","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1681\/ASN.V121194","article-title":"Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects","volume":"12","author":"Ecder","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2026071504090410700_hpag035-B30","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.ki.5000247","article-title":"Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease","volume":"69","author":"Agarwal","year":"2006","journal-title":"Kidney Int"},{"key":"2026071504090410700_hpag035-B31","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1523-1755.2005.00703.x","article-title":"Vasopressin antagonists in polycystic kidney disease","volume":"68","author":"Torres","year":"2005","journal-title":"Kidney Int"},{"key":"2026071504090410700_hpag035-B32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12882-017-0686-3","article-title":"Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study","volume":"18","author":"Al Therwani","year":"2017","journal-title":"BMC Nephrol"},{"key":"2026071504090410700_hpag035-B33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","article-title":"Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan","volume":"73","author":"Kramers","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026071504090410700_hpag035-B34","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10157-017-1475-9","article-title":"Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study","volume":"22","author":"Minami","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2026071504090410700_hpag035-B35","doi-asserted-by":"crossref","first-page":"F46","DOI":"10.1152\/ajprenal.2000.279.1.F46","article-title":"Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney","volume":"279","author":"Ecelbarger","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026071504090410700_hpag035-B36","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2169\/internalmedicine.55.7133","article-title":"Dual impact of tolvaptan on intracellular and extracellular water in chronic kidney disease patients with fluid retention","volume":"55","author":"Masuda","year":"2016","journal-title":"Intern Med"},{"key":"2026071504090410700_hpag035-B37","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/01.CIR.96.6.1859","article-title":"Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension","volume":"96","author":"Uzu","year":"1997","journal-title":"Circulation"},{"key":"2026071504090410700_hpag035-B38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0895-7061(01)02143-4","article-title":"Sleep quality and blood pressure dipping in obstructive sleep apnea","volume":"14","author":"Loredo","year":"2001","journal-title":"Am J Hypertens"},{"key":"2026071504090410700_hpag035-B39","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10157-021-02083-y","article-title":"Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO extension Japan","volume":"25","author":"Muto","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2026071504090410700_hpag035-B40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/HYPERTENSIONAHA.115.05820","article-title":"Reassessment of ambulatory blood pressure improves renal risk stratification in nondialysis chronic kidney disease: long-term cohort study","volume":"66","author":"Minutolo","year":"2015","journal-title":"Hypertension (Dallas, Tex: 1979)"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpag035\/68182434\/hpag035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/8\/1021\/68182434\/hpag035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/8\/1021\/68182434\/hpag035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:09:12Z","timestamp":1784102952000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/8\/1021\/8664425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,28]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpag035","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,4,28]]}}}